footandmouth
diseas
fmd
occur
anim
cloven
hoov
fmd
virus
fmdv
positivesens
singlestrand
rna
viru
belong
genu
aphthoviru
famili
picornavirida
size
viru
genom
approxim
kb
virus
classifi
seven
c
subtyp
fmd
outbreak
caus
reduct
product
infect
anim
eg
pig
cow
lamb
goat
cull
infect
anim
event
environment
contamin
loss
revenu
livestock
emerg
import
socioeconom
issu
thu
far
vaccin
prefer
method
prevent
fmdv
infect
howev
immun
respons
take
day
antivir
agent
use
chemic
compound
easili
synthes
scale
bulk
store
long
period
chemic
compound
stabl
biolog
addit
report
agent
act
directli
virus
rna
inhibitor
specif
certain
serotyp
thu
may
administ
anim
emerg
use
fmd
occur
fmd
never
erad
occur
mani
countri
world
regardless
research
antivir
agent
prevent
treat
fmdv
still
limit
past
two
decad
research
mutagen
nucleosid
analog
conduct
compound
agent
ribavirin
protect
rna
virus
favipiravir
deriv
exhibit
antivir
activ
high
dose
mgkgday
pig
also
report
pyrimidylthiophen
compound
show
antivir
activ
fmdvinfect
cell
anoth
studi
report
ribavirin
may
help
inhibit
replic
fmdv
cell
protect
transmiss
mice
antivir
agent
interferon
alpha
express
use
recombin
adenoviru
verifi
protect
effect
fmdv
pig
high
concentr
measur
serum
pig
verifi
effect
adenoviru
util
recombin
adenoviru
combin
inhibit
replic
fmdv
induc
delay
clinic
symptom
moreov
protect
fmdv
adult
mice
use
ifn
induc
polyinosin
poli
c
cpg
verifi
report
protect
fmdv
possibl
pig
use
ifn
combin
also
report
antivir
agent
compound
ifn
small
interf
rna
help
protect
fmd
antivir
agent
emerg
complement
earli
immun
vaccin
replac
vaccin
emerg
inocul
requir
reason
develop
appropri
antivir
agent
import
protect
fmd
prevent
transmiss
particular
one
report
state
treatment
ribavirin
along
chemic
agent
provid
excel
inhibitori
effect
rna
viru
replic
cell
guinea
pig
howev
report
ribavirin
effect
fmd
pig
studi
examin
abil
antivir
agent
inhibit
fmdv
replic
determin
whether
provid
protect
anim
seri
experi
conduct
determin
appropri
dosag
method
administr
even
though
limit
field
applic
ribavirin
dosedepend
side
effect
hemolyt
anemia
evalu
antivir
effect
proper
tool
overcom
disadvantag
fmdvinfect
cell
model
anim
demonstr
complementari
treatment
ribavirin
vaccin
synergist
effect
sustain
surviv
rate
bodi
weight
infect
anim
death
experiment
period
studi
intend
verifi
whether
ribavirin
appropri
inhibit
fmdv
replic
cell
prevent
clinic
diseas
laboratori
target
anim
without
side
effect
coadminist
agent
emerg
vaccin
earli
fmd
protect
swine
kidney
cell
cultur
day
incub
fetal
bovin
serum
fb
ph
antibiot
ad
minimum
essenti
mediumalpha
viru
titer
determin
fmdv
three
day
later
tissu
cultur
infect
dose
calcul
use
reed
muench
method
fmdv
genbank
access
use
challeng
pig
cell
cultur
day
incub
plate
inocul
fmdv
h
antivir
agent
ribavirin
sigma
usa
sigma
alfa
aesar
johnson
matthey
unit
kingdom
serial
dilut
ad
incub
cell
treat
h
mt
celltit
aqueou
one
solut
replic
assay
promega
usa
h
incub
absorb
measur
micropl
reader
nm
molecular
devic
usa
effect
concentr
cytotox
concentr
calcul
use
graphpad
graphpad
softwar
usa
effect
concentr
cytopath
effect
control
valu
standard
cytotox
concentr
normal
cell
account
total
cell
base
control
valu
tabl
inhibitori
effect
fmdv
replic
test
mice
use
ribavirin
recombin
adenovirus
antivir
agent
known
inhibit
rna
viru
replic
fig
sevenweekold
g
mice
purchas
orient
korea
intraperiton
ip
inocul
mg
ribavirin
perform
zero
three
day
mgdose
ribavirin
inject
ip
twice
per
day
day
day
mgdose
inject
ip
h
six
hour
agent
first
administ
mice
n
per
group
ip
inocul
lethal
dose
shamir
addit
posit
control
intramuscular
inocul
recombin
adenoviru
express
three
sirna
fmdv
express
concurr
inject
day
mous
challeng
day
challeng
viru
inject
ip
surviv
rate
mice
monitor
day
anim
treat
accord
ethic
guidelin
anim
welfar
committe
anim
plant
quarantin
agenc
apqa
anim
procedur
approv
institut
anim
care
use
committe
apqa
approv
effort
made
minim
anim
suffer
examin
antivir
activ
fmdv
use
variou
inocul
method
ribavirin
ip
intramuscularli
im
inject
day
day
panel
fig
six
hour
agent
first
provid
shamir
inject
ip
group
n
per
group
weight
chang
surviv
rate
mice
monitor
day
six
mg
per
day
ribavirin
suppli
pellet
feed
absorb
reagent
given
mice
n
per
group
day
panel
b
fig
six
hour
first
provis
reagent
shamir
inject
ip
weight
chang
surviv
rate
mice
monitor
day
addit
day
blood
collect
serum
prepar
rna
extract
measur
amount
viru
present
priocheck
fmdv
sp
prionic
switzerland
enzymelink
immunosorb
assay
elisa
kit
detect
fmdv
structur
protein
sp
antibodi
pig
serum
employ
detect
sp
antibodi
fmdv
day
trival
vaccin
administ
mg
mg
ribavirin
absorb
feed
provid
day
day
mous
fig
six
hour
vaccin
administr
provis
feed
reagent
absorb
mice
n
per
group
inject
ip
shamir
day
rechalleng
perform
shamir
chang
weight
surviv
rate
mice
monitor
day
adult
mice
divid
seven
group
includ
neg
control
group
parenter
model
anim
poor
appetit
fmd
infect
experiment
group
inocul
ip
mg
ribavirin
oilgel
adjuv
withwithout
commerci
vaccin
trival
vaccin
contain
manisa
iraq
shamir
boehring
ingelheim
anim
health
franc
day
fig
oil
adjuv
water
oil
water
type
montanid
isa
vg
seppic
franc
rehydragel
hpa
gener
chemic
usa
employ
adjuv
six
hour
drug
inject
mice
ip
inocul
shamir
anoth
group
condit
establish
hour
inocul
drug
day
mice
ip
inocul
shamir
chang
weight
surviv
rate
mice
monitor
day
addit
blood
collect
serum
separ
rna
extract
use
magnapur
lc
system
roch
switzerland
realtim
revers
transcriptas
polymeras
chain
reaction
realtim
rtpcr
conduct
quantifi
amount
fmdv
determin
potenti
protect
fmdv
challeng
im
inject
ribavirin
vaccin
specif
pathogenfre
spf
minipig
use
target
anim
model
tabl
yucatan
spf
mini
pig
weigh
kg
verifi
neg
fmdv
sp
antibodi
suppli
optifarm
solut
medipig
korea
anim
kept
care
apqa
use
approv
anim
care
use
committe
obtain
three
experiment
group
spf
pig
includ
neg
control
group
use
field
target
anim
test
day
spf
pig
n
per
group
administ
ribavirin
mgpig
dosag
determin
preliminari
dosedepend
survivalefficaci
test
pig
oil
adjuv
montanid
isa
vg
seppic
mix
weight
ratio
inject
im
ribavirinoil
compon
along
commerci
vaccin
trival
vaccin
contain
manisa
shamir
merial
immedi
afterward
pig
challeng
shamir
needl
challeng
heelbulb
blood
oral
swab
collect
serum
separ
rna
extract
use
magnapur
lc
system
roch
realtim
rtpcr
conduct
quantifi
amount
fmdv
clinic
observ
given
score
maximum
point
use
follow
criteria
lame
point
b
vesicl
hoof
foot
point
affect
hoof
foot
c
vesicl
snout
lip
tongu
point
affect
area
repeat
measur
analysi
varianc
anova
perform
use
graphpad
instat
ver
graphpad
softwar
graphpad
prism
graphpad
softwar
statist
assess
differ
surviv
rate
weight
chang
student
ttest
also
use
statist
signific
analysi
p
valu
smaller
indic
signific
differ
growth
inhibitori
effect
variou
antivir
agent
fmdv
measur
cell
select
index
ribavirin
highest
valu
tabl
regard
cell
toxic
ribavirin
azauridin
similar
valu
produc
lowest
reaction
cell
degre
resist
fmdv
ribavirin
abl
provid
antivir
effect
lowest
concentr
examin
whether
chemic
agent
ribavirin
azauridin
adenoviru
known
protect
rna
viru
replic
could
treat
protect
fmdv
fig
azauridin
tendenc
similar
neg
control
group
protect
fmdv
compar
treatment
quantiti
agent
adult
mice
inocul
surviv
rate
surviv
rate
howev
mg
ribavirin
administ
twice
day
day
day
mice
surviv
fig
examin
whether
differ
effect
ribavirin
protect
fmdv
depend
administr
rout
fig
ip
im
inocul
result
surviv
rate
mice
panel
fig
howev
weight
chang
rate
mice
compar
weight
chang
greatest
day
day
case
ip
inocul
day
day
case
im
inocul
thu
ip
inocul
effect
protect
fmdv
im
inocul
examin
whether
oral
administr
agent
absorb
feed
provid
protect
fmdv
panel
b
fig
daili
dose
increas
surviv
rate
mice
increas
mg
ribavirin
oral
administ
feed
surviv
rate
mice
day
ribavirin
oral
administ
feed
less
weight
chang
mice
case
administr
parenter
inject
efficaci
protect
fmd
mgday
oral
administr
surviv
rate
result
mgday
administ
group
treat
combin
applic
administ
vaccin
ribavirin
fig
vaccin
administ
day
mg
ribavirin
feed
oral
administ
day
day
adult
mice
significantli
high
surviv
rate
p
adult
mice
weight
chang
rate
fig
day
less
signific
daili
differ
mgday
ribavirin
oral
administ
feed
vaccin
given
group
low
surviv
rate
mice
die
day
challeng
inocul
fmdv
ribavirin
oral
administ
vaccin
inject
higher
concentr
antivir
agent
higher
surviv
rate
adult
mice
signific
differ
surviv
group
inocul
viru
addit
mg
mg
ribavirin
per
day
oral
administ
vaccin
given
daili
weight
chang
adult
mice
significantli
differ
inocul
day
adult
mice
challeng
concentr
fmdv
surviv
rate
weight
mice
chang
show
decreas
increas
pattern
chang
group
ribavirin
oral
administ
fmdv
detect
level
sera
similar
lower
control
group
day
fig
day
detect
fmdv
decreas
compar
day
group
isa
gel
rehydragel
hpa
use
adjuv
concomitantli
administ
ribavirin
fig
vaccin
alon
given
signific
differ
surviv
neg
control
p
ribavirin
concomitantli
inocul
adjuv
adjuv
vaccin
signific
differ
surviv
compar
control
group
p
adult
mice
inocul
fmdv
day
panel
fig
adult
mice
surviv
rate
higher
similar
mice
inocul
fmdv
twice
day
day
panel
b
fig
amount
fmdv
measur
serum
mice
day
postchalleng
dpc
panel
c
fig
amount
viru
group
lower
neg
control
fmdv
detect
regard
antivir
abil
ribavirin
sp
antibodi
fmdv
detect
day
postinfect
dpi
mgday
group
ribavirin
oral
administ
addit
mgday
group
ribavirin
oral
administ
along
vaccin
antibodi
detect
dpi
sp
antibodi
sp
elisa
vaccineonli
inject
group
detect
dpi
pig
administ
ribavirin
oil
adjuv
water
oil
water
observ
highest
clinic
score
point
within
dpc
tabl
anoth
group
inject
ribavirin
oil
commerci
vaccin
exhibit
clinic
sign
experiment
day
even
though
pig
expos
approxim
rna
copi
number
dpc
neg
control
found
high
rna
copi
number
viremia
tabl
great
deal
recent
research
aim
use
antivir
agent
prevent
spread
rna
virus
respons
varieti
diseas
compound
ribavirin
guanidinehcl
may
inhibit
replic
rna
virus
chikugunya
viru
semliki
forest
viru
coronaviru
vitro
gamma
provid
protect
rna
virus
hepat
c
viru
herp
simplex
viru
cytomegaloviru
among
differ
antivirus
oral
treatment
hepat
ribavirin
aerosol
ribavirin
respiratori
syncyti
viru
approv
food
drug
administr
present
studi
although
safe
dose
ribavirin
mice
pig
lower
mg
unpublish
ribavirin
provid
best
protect
effect
fmdv
among
differ
antivir
agent
known
defend
treat
rna
virus
given
mice
exhibit
high
surviv
rate
ribavirin
administ
consid
protect
transmiss
delay
effect
fmdv
rna
viru
regard
administr
pathway
system
applic
ip
rout
effect
local
applic
im
rout
observ
similar
result
studi
salazar
et
al
report
ip
administr
effect
simpl
oral
administr
oppos
inocul
inject
adult
mice
shown
protect
effect
fmdv
provis
agent
absorb
feed
effect
treat
fmd
oral
administr
ribavirin
agent
absorb
feed
almost
continu
oral
administr
maintain
vivo
concentr
howev
disadvantag
agent
administ
anim
voluntarili
consum
feed
thu
lack
appetit
may
accompani
infect
fmdv
may
result
lower
effect
although
differ
serotyp
fmdv
test
antivir
activ
use
effect
type
vivo
type
vitro
experi
shown
similar
tabl
fig
think
antivir
agent
may
commonli
effect
differ
serotyp
prior
research
guinea
pig
ip
inocul
ribavirin
mgkg
two
week
surviv
exposur
argentin
hemorrhag
fever
junin
viru
extend
day
similarli
anim
ip
inocul
mgkg
ribavirin
day
surviv
extend
day
result
show
life
extens
possibl
protect
incomplet
present
studi
measur
amount
fmdv
serum
mice
show
mgday
ribavirin
may
inhibit
replic
fmdv
within
approxim
day
mice
inocul
agent
along
vaccin
adjuv
use
concentr
ribavirin
reduc
mgday
result
surviv
adult
mice
consid
research
result
surviv
rate
heighten
adult
mice
inocul
oil
gel
adjuv
along
antivir
reagent
use
adjuv
antivir
agent
might
extend
antivir
reactiv
mice
outcom
prove
dose
inject
rather
method
administr
strongli
affect
reagent
protect
effect
fmdv
assum
target
anim
farm
typic
reinfect
fmdv
second
round
challeng
perform
condit
slight
weight
chang
chang
surviv
rate
thu
immun
gener
first
infect
may
protect
pathogen
reinfect
sp
antibodi
fmdv
detect
viru
replic
inhibit
vaccin
ribavirin
day
antivir
agent
ribavirin
help
delay
clinic
sign
pig
challeng
fmdv
pig
group
treat
ribavirin
vaccin
show
clinic
sign
measur
rna
copi
number
test
swab
therefor
think
ribavirin
excel
antivir
agent
protect
fmdv
provid
earli
immun
importantli
side
effect
consid
undertak
clinic
applic
ribavirin
report
ribavirintr
pig
show
signific
decreas
bodi
weight
redbloodcel
count
dpi
moreov
ribavirintr
fmdvuninfect
pig
clinic
sign
dyspnea
anorexia
weak
depress
present
day
conclus
lower
administr
amount
antivir
coadminist
adjuv
oil
gel
use
fmd
vaccin
enabl
protect
lethal
challeng
furthermor
administr
ribavirin
mgpig
along
fmd
vaccin
synergist
enhanc
antivir
activ
earli
viral
infect
futur
applic
determin
safe
effect
administr
amount
ribavirin
field
anim
cattl
pig
prioriti
addit
thorough
consider
method
administ
antivir
reagent
target
anim
well
number
administr
